N/A
N=20
Nebivolol in the Supine Hypertension of Autonomic Failure
Hypertension · Pure Autonomic Failure · Multiple System Atrophy
Bottom Line
View on ClinicalTrials.gov: NCT01044693 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
May 2015
Primary outcome: Primary: Change in Systolic Blood Pressure During the Night — 154; 162; 157; 158 mm Hg — p=0.036
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Placebo (Drug); Nebivolol 5 mg (Drug); metoprolol tartrate 50 mg (Drug); Sildenafil25 mg (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Vanderbilt University
- Primary completion
- Jul 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Systolic Blood Pressure During the Night |
154; 162; 157; 158; 1; -24 | 0.036 sig |
| SECONDARY Nocturnal Urinary Sodium Excretion |
0.145; 0.127; 0.139; 0.125 | 0.607 |
| SECONDARY Orthostatic Tolerance the Following Morning |
594; 675; 696; 575 | 0.597 |
| SECONDARY Change in Heart Rate During the Night |
-3; -6; -6; 0 | 0.996 |
Summary
The purpose of this study is to evaluate the effect of the antihypertensive drug, nebivolol (Bystolic), compared to metoprolol (Lopressor) and sildenafil (Viagra) on blood pressure in patients with autonomic failure and supine hypertension.
Eligibility Criteria
Inclusion Criteria
- Male or female and aged 18 years or over.
- Clinical diagnosis of orthostatic hypotension associated with Primary Autonomic Failure (Parkinson Disease, Multiple System Atrophy and Pure Autonomic Failure).
- A documented fall in systolic blood pressure of at least 20 mmHg, or in diastolic blood pressure of at least 10 mmHg, within 3 minutes after standing.
- Supine hypertension, defined as a systolic blood pressure >150 mm Hg or diastolic blood pressure > 90 mm Hg.
- Provide written informed consent to participate in the study and understand that they may withdraw their consent at any time without prejudice to their future medical care.
Exclusion Criteria
- Have changed dose, frequency and or type of prescribed medication, within two weeks of study start.
- Women of childbearing potential who are not using a medically accepted contraception.
- Have, in the investigator's opinion, any significant cardiac, systemic, hepatic, or renal illness.
- Diabetes mellitus or insipidus.
- In the investigator's opinion, have clinically significant abnormalities on clinical examination or laboratory testing.
- In the investigator's opinion, are unable to adequately co-operate because of individual or family situation.
- In the investigator's opinion, are suffering from a mental disorder that interferes with the diagnosis and/or with the conduct of the study, e.g. schizophrenia, major depression, dementia.
- Are not able or willing to comply with the study requirements for the duration of the study.
- Persons on drugs with beta-blocking potential (e.g., amiodarone), persons taking scheduled or as needed nitrates and persons on drugs with alpha-blocking potential (e.g. tamsulosin).
Data sourced from ClinicalTrials.gov (NCT01044693). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.